STAT3 and hematologic disorder: The compounds showing promising activity in targeting STAT3 in hematological malignancies include PY*LKTK, PY*L, AY*L [105], and ISS 610 [106], which are essentially small molecule peptidomimetics that interact with the SH2 domain, thereby preventing STAT dimerization and subsequent nuclear translocation and transcription.